Nonmuscle myosin light chain kinase activity modulates radiation-induced lung injury.
Author
Wang, TingMathew, Biji
Wu, Xiaomin
Shimizu, Yuka
Rizzo, Alicia N
Dudek, Steven M
Weichselbaum, Ralph R
Jacobson, Jeffrey R
Hecker, Louise
Garcia, Joe G N
Issue Date
2016-06
Metadata
Show full item recordCitation
Nonmuscle myosin light chain kinase activity modulates radiation-induced lung injury. 2016, 6 (2):234-9 Pulm CircJournal
Pulmonary circulationRights
© 2016 by the Pulmonary Vascular Research Institute. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Radiotherapy as a primary treatment for thoracic malignancies induces deleterious effects, such as acute or subacute radiation-induced lung injury (RILI). Although the molecular etiology of RILI is controversial and likely multifactorial, a potentially important cellular target is the lung endothelial cytoskeleton that regulates paracellular gap formation and the influx of macromolecules and fluid to the alveolar space. Here we investigate the central role of a key endothelial cytoskeletal regulatory protein, the nonmuscle isoform of myosin light chain kinase (nmMLCK), in an established murine RILI model. Our results indicate that thoracic irradiation significantly augmented nmMLCK protein expression and enzymatic activity in murine lungs. Furthermore, genetically engineered mice harboring a deletion of the nmMLCK gene (nmMLCK(-/-) mice) exhibited protection from RILI, as assessed by attenuated vascular leakage and leukocyte infiltration. In addition, irradiated wild-type mice treated with two distinct MLCK enzymatic inhibitors, ML-7 and PIK (peptide inhibitor of kinase), also demonstrated attenuated RILI. Taken together, these data suggests a key role for nmMLCK in vascular barrier regulation in RILI and warrants further examination of RILI strategies that target nmMLCK.Note
Electronically published April 19, 2016. 12 month embargo.ISSN
2045-8932PubMed ID
27252850DOI
10.1086/686491Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1086/686491
Scopus Count
Collections
Related articles
- Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury.
- Authors: Mirzapoiazova T, Moitra J, Moreno-Vinasco L, Sammani S, Turner JR, Chiang ET, Evenoski C, Wang T, Singleton PA, Huang Y, Lussier YA, Watterson DM, Dudek SM, Garcia JG
- Issue date: 2011 Jan
- Critical role for the lung endothelial nonmuscle myosin light-chain kinase isoform in the severity of inflammatory murine lung injury.
- Authors: Kempf CL, Sammani S, Bermudez T, Song JH, Hernon VR, Hufford MK, Burt J, Camp SM, Dudek SM, Garcia JGN
- Issue date: 2022 Apr
- Sp1-mediated nonmuscle myosin light chain kinase expression and enhanced activity in vascular endothelial growth factor-induced vascular permeability.
- Authors: Shimizu Y, Camp SM, Sun X, Zhou T, Wang T, Garcia JG
- Issue date: 2015 Dec
- Nonmuscle myosin light chain kinase regulates murine asthmatic inflammation.
- Authors: Wang T, Moreno-Vinasco L, Ma SF, Zhou T, Shimizu Y, Sammani S, Epshtein Y, Watterson DM, Dudek SM, Garcia JG
- Issue date: 2014 Jun
- Proline-rich region of non-muscle myosin light chain kinase modulates kinase activity and endothelial cytoskeletal dynamics.
- Authors: Belvitch P, Adyshev D, Elangovan VR, Brown ME, Naureckas C, Rizzo AN, Siegler JH, Garcia JG, Dudek SM
- Issue date: 2014 Sep